Am­gen, Ipsen vet moves up the lad­der with Co­herus' an­ti-PD-1 await­ing PDU­FA; It takes a vil­lage to re­place Frank Clyburn at Mer­ck­'s Hu­man Health busi­ness

Af­ter decades in the bio­phar­ma in­dus­try, Paul Rei­der is now in his first C-suite role as chief com­mer­cial of­fi­cer. While he has been at Co­herus Bio­Sciences since last year, he of­fi­cial­ly start­ed his new job on Jan. 1, and it was pub­licly an­nounced on Tues­day.

The ap­point­ment will place Rei­der right in the thick­et of the biggest is­sues in can­cer drug de­vel­op­ment. Long a play­er in the biosim­i­lar world, Co­herus spent $150 mil­lion last year to li­cense a PD-1 from Shang­hai’s Jun­shi Bio­sciences, join­ing up to three oth­er ma­jor US com­pa­nies that promised to un­der­cut the high-priced mar­ket for PD-1 in­hibitors by bring­ing in Chi­nese drugs and sell­ing them well be­low the price of Keytru­da or Op­di­vo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER